Somewhat Favorable News Coverage Somewhat Unlikely to Impact Bristol-Myers Squibb (BMY) Share Price
Media coverage about Bristol-Myers Squibb (NYSE:BMY) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9162346323446 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- The Klein Law Firm Announces a Class Action Filed on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY) (markets.financialcontent.com)
- Bristol-Myers Squibb Co (BMY) Shares Sold by TCI Wealth Advisors Inc. (americanbankingnews.com)
- Bristol-Myers Squibb Co (BMY) Shares Sold by State Treasurer State of Michigan (americanbankingnews.com)
- Bristol-Myers Squibb (BMY) Price Target Raised to $68.00 (americanbankingnews.com)
- [$$] Immunotherapy: beyond melanoma and lung cancer treatment (finance.yahoo.com)
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up $0.65 on Monday, reaching $66.82. The company’s stock had a trading volume of 5,231,876 shares, compared to its average volume of 8,980,000. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The company has a market cap of $109,360.00, a price-to-earnings ratio of 28.31, a P/E/G ratio of 2.06 and a beta of 0.98. Bristol-Myers Squibb has a 1 year low of $51.56 and a 1 year high of $70.05.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 67.80%.
A number of research analysts have recently issued reports on the company. Jefferies Group set a $72.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 26th. Bank of America boosted their price objective on Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a research note on Monday. DZ Bank downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price objective on the stock in a research note on Thursday, February 1st. Finally, BMO Capital Markets set a $51.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday, February 14th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $66.30.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction dated Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2018/03/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-bristol-myers-squibb-bmy-share-price.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.